Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 4;15(3):3464–3471. doi: 10.3892/ol.2018.7728

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Xie et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — Serum miR-96 was highly expressed in patients with breast cancer and associated with breast cancer prognosis. (A) Serum miR-96 levels from patients with breast cancer (n=44), benign breast tumors (n=18) and health controls (n=18) were detected with RT-qPCR. *P<0.05 vs. adjacent benign breast tumors. (B) miR-96 levels in patients with breast cancer prior and subsequent to chemotherapy were detected with RT-qPCR. *P<0.05 vs. breast patients prior to chemotherapy. Serum miR-96 levels in patients with (C) estrogen receptor (ER)+ and ER-, (D) progesterone receptor (PR)+ and PR- and (E) HER2+ and HER2-breast cancer were detected with RT-qPCR. (F) Serum miR-96 levels in patients with clinical stages I, II, III and IV were detected with RT-qPCR. RT-qPCR, reverse transcription quantitative polymerase chain reaction; miR, microRNA; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2.